Extract from the Register of European Patents

EP About this file: EP2358746

EP2358746 - BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.07.2021
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  14.08.2020
FormerGrant of patent is intended
Status updated on  01.04.2020
FormerExamination is in progress
Status updated on  21.02.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK
published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Molecular Partners AG
Wagistrasse 14
8952 Schlieren / CH
[2011/34]
Inventor(s)01 / BINZ, Hans Kaspar
Lüssirainstrasse 52
6300 Zug / CH
02 / FORRER, Patrik
Unterfeld 6
6422 Steinen / CH
03 / STUMPP, Michael Tobias
Chratzstrasse 6
8954 Geroldswil / CH
 [2020/38]
Former [2011/34]01 / BINZ, Hans Kaspar
Bachstrasse 27
CH-8903 Birnensdorf / CH
02 / FORRER, Patrik
Rainackerstrasse 17
CH-8953 Dietikon / CH
03 / STUMPP, Michael Tobias
Chratzstrasse 6
CH-8954 Geroldswil / CH
Representative(s)Latscha Schöllhorn Partner AG
Grellingerstrasse 60
4052 Basel / CH
[2020/38]
Former [2014/43]Latscha Schöllhorn Partner
Latscha Schöllhorn Partner AG
Austrasse 24
4051 Basel / CH
Former [2011/34]Becker, Konrad
Aeschenvorstadt 24 Postfach 318
4010 Basel / CH
Application number, filing date09756279.703.11.2009
[2011/34]
WO2009EP64483
Priority number, dateEP2008016816603.11.2008         Original published format: EP 08168166
[2011/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010060748
Date:03.06.2010
Language:EN
[2010/22]
Type: A1 Application with search report 
No.:EP2358746
Date:24.08.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 03.06.2010 takes the place of the publication of the European patent application.
[2011/34]
Type: B1 Patent specification 
No.:EP2358746
Date:16.09.2020
Language:EN
[2020/38]
Search report(s)International search report - published on:EP03.06.2010
ClassificationIPC:C07K14/47, A61K38/00, A61K47/60
[2020/11]
CPC:
C07K14/47 (EP,KR,RU,US); A61K38/00 (EP,CN,RU,US); C07K14/4703 (CN,RU,US);
A61K38/17 (KR,RU); A61K47/60 (EP,RU,US); A61P27/02 (EP);
A61P35/00 (EP); A61P9/00 (EP); A61P9/12 (EP);
C07K14/515 (RU); C12N15/11 (KR) (-)
Former IPC [2011/34]C07K14/47
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2020/38]
Former [2011/34]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:BINDUNGSPROTEINE ZUM HEMMEN DER VEGF-A-REZEPTORINTERAKTION[2020/18]
English:BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION[2011/34]
French:PROTÉINES DE LIAISON INHIBANT L'INTERACTION DU RÉCEPTEUR VEGF-A[2020/18]
Former [2011/34]DIE VEGF-A-REZEPTOR-WECHSELWIRKUNG INHIBIERENDE BINDUNGSPROTEINE
Former [2011/34]PROTÉINES DE LIAISON INHIBANT L INTERACTION DU RÉCEPTEUR VEGF-A
Entry into regional phase20.05.2011National basic fee paid 
20.05.2011Designation fee(s) paid 
20.05.2011Examination fee paid 
Examination procedure20.05.2011Examination requested  [2011/34]
22.12.2011Amendment by applicant (claims and/or description)
15.01.2015Despatch of a communication from the examining division (Time limit: M06)
20.07.2015Reply to a communication from the examining division
09.10.2015Despatch of a communication from the examining division (Time limit: M06)
18.04.2016Reply to a communication from the examining division
17.10.2016Despatch of a communication from the examining division (Time limit: M06)
10.04.2017Reply to a communication from the examining division
17.08.2017Despatch of a communication from the examining division (Time limit: M06)
22.02.2018Reply to a communication from the examining division
31.05.2018Despatch of a communication from the examining division (Time limit: M06)
07.12.2018Reply to a communication from the examining division
11.04.2019Despatch of a communication from the examining division (Time limit: M06)
18.10.2019Reply to a communication from the examining division
02.04.2020Communication of intention to grant the patent
06.08.2020Fee for grant paid
06.08.2020Fee for publishing/printing paid
06.08.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20196328.7  / EP3785735
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.01.2015
Opposition(s)17.06.2021No opposition filed within time limit [2021/34]
Fees paidRenewal fee
23.11.2011Renewal fee patent year 03
23.11.2012Renewal fee patent year 04
28.11.2013Renewal fee patent year 05
25.11.2014Renewal fee patent year 06
24.11.2015Renewal fee patent year 07
23.11.2016Renewal fee patent year 08
24.11.2017Renewal fee patent year 09
22.11.2018Renewal fee patent year 10
26.11.2019Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.11.2009
AT16.09.2020
CY16.09.2020
CZ16.09.2020
EE16.09.2020
FI16.09.2020
HR16.09.2020
LT16.09.2020
LV16.09.2020
MC16.09.2020
MK16.09.2020
MT16.09.2020
RO16.09.2020
SI16.09.2020
SK16.09.2020
SM16.09.2020
LU03.11.2020
BG16.12.2020
GR17.12.2020
IS16.01.2021
PT18.01.2021
[2022/32]
Former [2022/27]HU03.11.2009
AT16.09.2020
CY16.09.2020
CZ16.09.2020
EE16.09.2020
FI16.09.2020
HR16.09.2020
LT16.09.2020
LV16.09.2020
MC16.09.2020
MT16.09.2020
RO16.09.2020
SI16.09.2020
SK16.09.2020
SM16.09.2020
LU03.11.2020
BG16.12.2020
GR17.12.2020
IS16.01.2021
PT18.01.2021
Former [2021/36]AT16.09.2020
CZ16.09.2020
EE16.09.2020
FI16.09.2020
HR16.09.2020
LT16.09.2020
LV16.09.2020
MC16.09.2020
RO16.09.2020
SI16.09.2020
SK16.09.2020
SM16.09.2020
LU03.11.2020
BG16.12.2020
GR17.12.2020
IS16.01.2021
PT18.01.2021
Former [2021/33]AT16.09.2020
CZ16.09.2020
EE16.09.2020
FI16.09.2020
HR16.09.2020
LT16.09.2020
LV16.09.2020
MC16.09.2020
RO16.09.2020
SK16.09.2020
SM16.09.2020
LU03.11.2020
BG16.12.2020
GR17.12.2020
IS16.01.2021
PT18.01.2021
Former [2021/31]AT16.09.2020
CZ16.09.2020
EE16.09.2020
FI16.09.2020
HR16.09.2020
LT16.09.2020
LV16.09.2020
MC16.09.2020
RO16.09.2020
SK16.09.2020
SM16.09.2020
BG16.12.2020
GR17.12.2020
IS16.01.2021
PT18.01.2021
Former [2021/28]AT16.09.2020
CZ16.09.2020
EE16.09.2020
FI16.09.2020
HR16.09.2020
LT16.09.2020
LV16.09.2020
RO16.09.2020
SK16.09.2020
SM16.09.2020
BG16.12.2020
GR17.12.2020
IS16.01.2021
PT18.01.2021
Former [2021/25]AT16.09.2020
CZ16.09.2020
EE16.09.2020
FI16.09.2020
HR16.09.2020
LT16.09.2020
LV16.09.2020
RO16.09.2020
SM16.09.2020
BG16.12.2020
GR17.12.2020
IS16.01.2021
PT18.01.2021
Former [2021/24]AT16.09.2020
CZ16.09.2020
EE16.09.2020
FI16.09.2020
HR16.09.2020
LT16.09.2020
LV16.09.2020
RO16.09.2020
SM16.09.2020
BG16.12.2020
GR17.12.2020
PT18.01.2021
Former [2021/23]CZ16.09.2020
EE16.09.2020
FI16.09.2020
HR16.09.2020
LT16.09.2020
LV16.09.2020
RO16.09.2020
SM16.09.2020
BG16.12.2020
GR17.12.2020
PT18.01.2021
Former [2021/22]CZ16.09.2020
EE16.09.2020
FI16.09.2020
HR16.09.2020
LT16.09.2020
LV16.09.2020
RO16.09.2020
BG16.12.2020
GR17.12.2020
PT18.01.2021
Former [2021/21]FI16.09.2020
HR16.09.2020
LT16.09.2020
LV16.09.2020
BG16.12.2020
GR17.12.2020
PT18.01.2021
Former [2021/20]FI16.09.2020
HR16.09.2020
LT16.09.2020
LV16.09.2020
BG16.12.2020
GR17.12.2020
Former [2021/10]FI16.09.2020
HR16.09.2020
LV16.09.2020
BG16.12.2020
GR17.12.2020
Former [2021/08]FI16.09.2020
BG16.12.2020
Cited inInternational search[A] WO0220565  (UNIV ZUERICH et al.) [A] 1-20 * the whole document *
 [A] WO2005056764  (COMPOUND THERAPEUTICS INC et al.) [A] 1-20
 [A] WO2008066752  (ADNEXUS A BRISTOL MEYERS SQUIB et al.) [A] 1-20
 [XY]   INOKI ISAO ET AL: "Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis.", THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY FEB 2002 LNKD- PUBMED:11744618, vol. 16, no. 2, February 2002 (2002-02-01), pages 219 - 221, XP002577430, ISSN: 1530-6860 [X] 1 * the whole document *[Y] 2-20
 [Y]   STUMPP M T ET AL: "DARPins: A new generation of protein therapeutics", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US LNKD- DOI:10.1016/J.DRUDIS.2008.04.013, vol. 13, no. 15-16, 1 August 2008 (2008-08-01), pages 695 - 701, XP023440383, ISSN: 1359-6446, [retrieved on 20080711] [Y] 2-20 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.drudis.2008.04.013
 [A]   FORRER P ET AL: "Consensus design of repeat proteins", CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, WILEY VCH, WEINHEIM, DE LNKD- DOI:10.1002/CBIC.200300762, vol. 5, no. 2, 6 February 2004 (2004-02-06), pages 183 - 189, XP002382372, ISSN: 1439-4227 [A] 1-20

DOI:   http://dx.doi.org/10.1002/cbic.200300762
 [A]   BINZ H K ET AL: "Designing Repeat Proteins: Well-expressed, Soluble and Stable Proteins from Combinatorial Libraries of Consensus Ankyrin Repeat Proteins", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 332, no. 2, 12 September 2003 (2003-09-12), pages 489 - 503, XP004450112, ISSN: 0022-2836 [A] 1-20

DOI:   http://dx.doi.org/10.1016/S0022-2836(03)00896-9
 [A]   BINZ H KASPAR ET AL: "High-affinity binders selected from designed ankyrin repeat protein libraries", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 22, no. 5, 1 May 2004 (2004-05-01), pages 575 - 582, XP002343919, ISSN: 1087-0156 [A] 1-20

DOI:   http://dx.doi.org/10.1038/nbt962
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.